Making p38 MAP kinase inhibition viable
The inhibition of the validated drug target p38 MAP kinase has been shown by many big...
Read moreDivisional growth on track, group scaling up
The interim results were a strong reminder that operationally RQIH remains on track to meet its...
Read moreQ3 update: Positive outlook in uncertain times
Benchmark’s results for the FY22 Q3 (April-June) period showed robust sales plus adjusted EBITDA...
Read more
First corner turned
After a period of sub-optimal performance, Gattaca - the UK's largest specialist engineering/tech...
Read moreSolid as a rock
Vp – a specialist equipment rental firm - indicated last Tuesday that it remained on track to meet...
Read moreStrong operational progress to give perspective
Only two months ago shareholders saw sufficient potential upside to reject a bid at c. 128p...
Read moreStake in 8AM acquired, net inflows solid
Tatton has now concluded the acquisition of 50% of 8AM Global Limited (8AM) for a total...
Read morePositive AGM Statement
RUA Life Sciences’ AGM statement led with an update on its two revenue-generating businesses for...
Read moreUPGS - record sales and profits in FY2022
A 13% increase in net sales revenue to a record £154.2m, a 41% increase in EBITDA to £18.8m (also a...
Read moreFY22 results – Record orders bode well
We initiate coverage on Cohort Group with a Fair Value of 650p/share. Clearly the nature and...
Read moreMarket share gains drive revenue growth
Significant market share gains in a particularly tough market environment were responsible for...
Read moreRegister to be first
Get research on the companies that interest you straight to your inbox
